Refine
Year of publication
Document Type
- Preprint (673)
- Article (461)
- Conference Proceeding (4)
- magisterthesis (1)
- Working Paper (1)
Has Fulltext
- yes (1140)
Is part of the Bibliography
- no (1140)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- inflammation (6)
- macrophage (6)
- cancer (5)
- sphingosine-1-phosphate (5)
- ALICE experiment (4)
- Collective Flow (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- apoptosis (4)
- reactive oxygen species (4)
- tumor microenvironment (4)
- ALICE (3)
- Heavy Ions (3)
- Immunology (3)
- Jets and Jet Substructure (3)
- lipocalin-2 (3)
- macrophage polarization (3)
- macrophages (3)
- pp collisions (3)
- psoriasis (3)
- Atmospheric science (2)
- Beauty production (2)
- Breast cancer (2)
- Breast tumors (2)
- Charm physics (2)
- Climate change (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Gene expression (2)
- Heavy Quark Production (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Macrophages (2)
- Nrf2 (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- QCD (2)
- Single electrons (2)
- angiogenesis (2)
- atherosclerosis (2)
- chemotherapy (2)
- iron (2)
- lung cancer (2)
- phagocytosis (2)
- sepsis (2)
- 900 GeV (1)
- ALICE detector (1)
- Acute inflammation (1)
- Adjuvant procedure (1)
- Adjuvantes Verfahren (1)
- Advanced breast cancer (1)
- Aggression (1)
- Angioplasty (1)
- Anti-nuclei (1)
- Antihormone therapy (1)
- Atmospheric chemistry (1)
- Biomarker (1)
- Biomarkers (1)
- Bipolar disorder (1)
- Boosted Jets (1)
- CLOUD experiment (1)
- COVID-19 (1)
- Cancer (1)
- Cancer genomics (1)
- Careers (1)
- Cell binding (1)
- Cell staining (1)
- Centrality Class (1)
- Centrality Selection (1)
- Circadian (1)
- Clinical Trials and Observations (1)
- Collective Flow, (1)
- Comparison with QCD (1)
- Cytoskeleton (1)
- DNA methylation (1)
- Decision making (1)
- Diagnostic medicine (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Environmental impacts (1)
- Epigenetics (1)
- Erzähltechnik (1)
- Extended donor criteria (1)
- Extracellular vesicles (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Flow cytometry (1)
- Functional mitral regurgitation (1)
- G2A (1)
- GEMs (1)
- GPCR (1)
- Gene/Regulation (1)
- Genetic loci (1)
- Genetic networks (1)
- Genetics (1)
- Glycolysis (1)
- HBT (1)
- HCC marker (1)
- HDAC (1)
- HER2 c-erbB2 (1)
- HER2/neu (1)
- HIF-2 (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hard Scattering (1)
- Health care sector (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Hemodynamics (1)
- Hepatocellular carcinoma (1)
- Heregulin (1)
- Hypoxia (1)
- IFN-β (1)
- IL-1β (1)
- IL-27 cytokine (1)
- ISR (1)
- Immune cells (1)
- Immunogenetics (1)
- Inclusive spectra (1)
- Inflammation (1)
- Intensity interferometry (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Iron (1)
- Jet Physics (1)
- Jet Substructure (1)
- Kupffer cells (1)
- LDHB (1)
- Langzeiteffekt (1)
- Long-term effect (1)
- Lymphocytes (1)
- Lymphoid tissues (1)
- MAGGIC score (1)
- MM-121 (1)
- Macrophage (1)
- Material budget (1)
- Mechanism of action (1)
- Medical education (1)
- Messenger RNA (1)
- Metastatic (1)
- Methylation (1)
- Meyrink, Gustav / Der Golem (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Mitochondrial ROS (1)
- MitraClip (1)
- Monte Carlo (1)
- Mouse models (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Myeloid Neoplasia (1)
- Mφs (1)
- NADPH oxidase (1)
- NLRP3 inflammasomes (1)
- Natriuretic peptide (1)
- Neural network (1)
- Neuromodulatorisches Netzwerk (1)
- Neuromodulatory network (1)
- Neurostimulation (1)
- Nuclear modification factor (1)
- Oncology (1)
- Organ allocation (1)
- Oxidative phosphorylation (1)
- PCR (1)
- PD-L1 (1)
- PYTHIA (1)
- Pancreas transplantation (1)
- Particle and Resonance Production (1)
- Pb–Pb (1)
- Peritoneal macrophages (1)
- Physiology (1)
- Production Cross Section (1)
- Professions (1)
- Properties of Hadrons (1)
- Proton–proton (1)
- Psychiatric disorders (1)
- Psychiatry (1)
- Pulmonary embolism (1)
- Pulmonary hypertension (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- RNA extraction (1)
- RNA isolation (1)
- RNA sequencing (1)
- RNA therapeutics (1)
- RNA/MicroRNA (1)
- ROS (1)
- Rapidity Range (1)
- Receptors/Nuclear (1)
- Rejection (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- S1PR1 (1)
- S1PR4 (1)
- SARS-CoV-2 (1)
- SLC7A11 (1)
- STAT1 (1)
- Seasonal variation (1)
- Seattle heart failure model (1)
- Seribantumab (1)
- Single muons (1)
- Solar insolation (1)
- Suicide (1)
- Sunlight (1)
- Surgeons (1)
- Surgical and invasive medical procedures (1)
- Systematic Uncertainty (1)
- T-DM1 (1)
- TAPSE (1)
- TR (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Troponin (1)
- Undergraduates (1)
- Vector Boson Production (1)
- Wirkmechanismus (1)
- Xenon-based gas mixture (1)
- Zymosan-induced peritonitis (1)
- acute inflammation (1)
- advanced breast cancer (1)
- aerosol formation (1)
- aerosols (1)
- alcoholic hepatitis (1)
- antihormone therapy (1)
- antioxidants (1)
- arachidonate 12/15-lipoxygenase (Alox12/15) (1)
- area expansion (1)
- breast cancer (1)
- breast tumor (1)
- cancer metastases (1)
- cancer-associated fibroblasts (1)
- costimulation (1)
- cytokine (1)
- cytokine, angiogenesis (1)
- cytotoxic T cells (1)
- cytotoxic lymphocytes (1)
- cytotoxicity (1)
- dE/dx (1)
- detector (1)
- diabetic nephropathy (1)
- diagnostic test (1)
- drug discovery (1)
- efferocytosis (1)
- electrophiles (1)
- endothelial cell (1)
- envenomation (1)
- epigenetic (1)
- erastin (1)
- experimental results (1)
- extracellular signal-regulated kinase (1)
- fatty acid (1)
- ferroportin (1)
- ferroptosis (1)
- flow cytometry (1)
- gene expression (1)
- gene signature (1)
- head-and-neck cancer (1)
- heavy ion experiments (1)
- hierarchical clustering (1)
- hypoxia (1)
- immune checkpoint (1)
- immunity (1)
- immunotherapy (1)
- infection (1)
- invasive species (1)
- inflammation (1)
- iron-trafficking (1)
- lapatinib (1)
- lipids (1)
- lipoproteins (1)
- lipoxin A4 (1)
- liver (1)
- liver X receptor (1)
- lung tumor heterogeneity (1)
- lymphangiogenesis (1)
- mammary cancer (1)
- mammary carcinoma (1)
- mast cells (1)
- metabolism (1)
- metastasis (1)
- metastatic (1)
- miR (1)
- microenvironment (1)
- migration (1)
- multispectral flow cytometry (1)
- nanoparticle growth (1)
- natural killer T cells (1)
- nuclear factor 2 (erythroid-derived 2-like factor) (NFE2L2) (Nrf2) (1)
- oxidative stress (1)
- oxidized low density lipoprotein (1)
- p-eIF2α (1)
- pain (1)
- peritoneal macrophages (1)
- peroxisome proliferator-activated receptor (1)
- pertuzumab (1)
- polarization (1)
- polyunsaturated fatty acid (1)
- proliferation (1)
- prostaglandins (1)
- protein-protein interaction (1)
- proteomics (1)
- quark gluon plasma (1)
- renal cell carcinoma (1)
- resolution (1)
- resolution of inflammation (1)
- signal transduction (1)
- specialized pro-resolving lipid mediators (SPMs) (1)
- spectra (1)
- spider hysteria (1)
- toll-like receptor (1)
- transcription factor (1)
- transcriptional profiling (1)
- transcriptome (1)
- trastuzumab (1)
- tumor progression (1)
- tumor stroma (1)
- tumor-associated macrophages (1)
- tumor-associated macrophages (TAM) (1)
- volatile organic compounds (1)
- yellow sac spiders (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1053)
- Frankfurt Institute for Advanced Studies (FIAS) (955)
- Informatik (921)
- Medizin (72)
- Sonderforschungsbereiche / Forschungskollegs (20)
- Biochemie und Chemie (7)
- Geowissenschaften (4)
- Geowissenschaften / Geographie (3)
- Informatik und Mathematik (3)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (3)
Rapidity and transverse momentum dependence of inclusive J/ψ production in pp collisions at √s=7 TeV
(2011)
The ALICE experiment at the LHC has studied inclusive J/ψ production at central and forward rapidities in pp collisions at √s=7 TeV. In this Letter, we report on the first results obtained detecting the J/ψ through the dilepton decay into e+e− and μ+μ− pairs in the rapidity ranges |y|<0.9 and 2.5<y<4, respectively, and with acceptance down to zero pT. In the dielectron channel the analysis was carried out on a data sample corresponding to an integrated luminosity Lint=5.6 nb−1 and the number of signal events is NJ/ψ=352±32(stat.)±28(syst.); the corresponding figures in the dimuon channel are Lint=15.6 nb−1 and NJ/ψ=1924±77(stat.)±144(syst.). The measured production cross sections are σJ/ψ(|y|<0.9)=10.7±1.0(stat.)±1.6(syst.)−2.3+1.6(syst.pol.)μb and σJ/ψ(2.5<y<4)=6.31±0.25(stat.)±0.76(syst.)−1.96+0.95(syst.pol.)μb. The differential cross sections, in transverse momentum and rapidity, of the J/ψ were also measured.
The nuclear factor kappa beta (NFκB) signaling pathway plays an important role in liver homeostasis and cancer development. Tax1-binding protein 1 (Tax1BP1) is a regulator of the NFκB signaling pathway, but its role in the liver and hepatocellular carcinoma (HCC) is presently unknown. Here we investigated the role of Tax1BP1 in liver cells and murine models of HCC and liver fibrosis. We applied the diethylnitrosamine (DEN) model of experimental hepatocarcinogenesis in Tax1BP1+/+ and Tax1BP1−/− mice. The amount and subsets of non-parenchymal liver cells in in Tax1BP1+/+ and Tax1BP1−/− mice were determined and activation of NFκB and stress induced signaling pathways were assessed. Differential expression of mRNA and miRNA was determined. Tax1BP1−/− mice showed increased numbers of inflammatory cells in the liver. Furthermore, a sustained activation of the NFκB signaling pathway was found in hepatocytes as well as increased transcription of proinflammatory cytokines in isolated Kupffer cells from Tax1BP1−/− mice. Several differentially expressed mRNAs and miRNAs in livers of Tax1BP1−/− mice were found, which are regulators of inflammation or are involved in cancer development or progression. Furthermore, Tax1BP1−/− mice developed more HCCs than their Tax1BP1+/+ littermates. We conclude that Tax1BP1 protects from liver cancer development by limiting proinflammatory signaling.
Recent studies suggested an important contribution of sphingosine-1-phospate (S1P) signaling via its specific receptors (S1PRs) in the production of pro-inflammatory mediators such as Interleukin (IL)-1β in cancer and inflammation. In an inflammation-driven cancer setting, we previously reported that myeloid S1PR1 signaling induces IL-1β production by enhancing NLRP3 (NOD-, LRR- and Pyrin Domain-Containing Protein 3) inflammasome activity. However, the autocrine role of S1P and enzymes acting on the S1P rheostat in myeloid cells are unknown. Using human and mouse macrophages with pharmacological or genetic intervention we explored the relative contribution of sphingosine kinases (SPHKs) in NLRP3 inflammasome activity regulation. We noticed redundancy in SPHK1 and SPHK2 activities towards macrophage NLRP3 inflammasome transcriptional induction and IL-1β secretion. However, pharmacological blockade of both kinases in unison completely abrogated NLRP3 inflammasome induction and IL-1β secretion. Interestingly, human and mouse macrophages demonstrate varied responses towards SPHKs inhibition and IL-1β secretion. Clinical datasets of renal cell carcinoma and psoriasis patients showed a positive correlation between enzymes affecting the S1P rheostat with NLRP3 inflammasome components expression, which corroborates our finding. Our data provide a better understanding on the role of SPHKs and de novo synthesized S1P in macrophage NLRP3 inflammasome activation
Macrophages supply iron to the breast tumor microenvironment by enforced secretion of lipocalin-2 (Lcn-2)-bound iron as well as the increased expression of the iron exporter ferroportin (FPN). We aimed at identifying the contribution of each pathway in supplying iron for the growing tumor, thereby fostering tumor progression. Analyzing the expression profiles of Lcn-2 and FPN using the spontaneous polyoma-middle-T oncogene (PyMT) breast cancer model as well as mining publicly available TCGA (The Cancer Genome Atlas) and GEO Series(GSE) datasets from the Gene Expression Omnibus database (GEO), we found no association between tumor parameters and Lcn-2 or FPN. However, stromal/macrophage-expression of Lcn-2 correlated with tumor onset, lung metastases, and recurrence, whereas FPN did not. While the total iron amount in wildtype and Lcn-2−/− PyMT tumors showed no difference, we observed that tumor-associated macrophages from Lcn-2−/− compared to wildtype tumors stored more iron. In contrast, Lcn-2−/− tumor cells accumulated less iron than their wildtype counterparts, translating into a low migratory and proliferative capacity of Lcn-2−/− tumor cells in a 3D tumor spheroid model in vitro. Our data suggest a pivotal role of Lcn-2 in tumor iron-management, affecting tumor growth. This study underscores the role of iron for tumor progression and the need for a better understanding of iron-targeted therapy approaches.
Sepsis is characterized by dysregulated gene expression, provoking a hyper-inflammatory response occurring in parallel to a hypo-inflammatory reaction. This is often associated with multi-organ failure, leading to the patient’s death. Therefore, reprogramming of these pro- and anti-inflammatory, as well as immune-response genes which are involved in acute systemic inflammation, is a therapy approach to prevent organ failure and to improve sepsis outcomes. Considering epigenetic, i.e., reversible, modifications of chromatin, not altering the DNA sequence as one tool to adapt the expression profile, inhibition of factors mediating these changes is important. Acetylation of histones by histone acetyltransferases (HATs) and initiating an open-chromatin structure leading to its active transcription is counteracted by histone deacetylases (HDACs). Histone deacetylation triggers a compact nucleosome structure preventing active transcription. Hence, inhibiting the activity of HDACs by specific inhibitors can be used to restore the expression profile of the cells. It can be assumed that HDAC inhibitors will reduce the expression of pro-, as well as anti-inflammatory mediators, which blocks sepsis progression. However, decreased cytokine expression might also be unfavorable, because it can be associated with decreased bacterial clearance.
Carcinogenesis is a multistep process. Besides somatic mutations in tumor cells, stroma-associated immunity is a major regulator of tumor growth. Tumor cells produce and secrete diverse mediators to create a local microenvironment that supports their own survival and growth. It is becoming apparent that iron acquisition, storage, and release in tumor cells is different from healthy counterparts. It is also appreciated that macrophages in the tumor microenvironment acquire a tumor-supportive, anti-inflammatory phenotype that promotes tumor cell proliferation, angiogenesis, and metastasis. Apparently, this behavior is attributed, at least in part, to the ability of macrophages to support tumor cells with iron. Polarization of macrophages by apoptotic tumor cells shifts the profile of genes involved in iron metabolism from an iron sequestering to an iron-release phenotype. Iron release from macrophages is supposed to be facilitated by ferroportin. However, lipid mediators such as sphingosine-1-phosphate, released form apoptotic tumor cells, upregulate lipocalin-2 (Lcn-2) in macrophages. This protein is known to bind siderophore-complexed iron and thus, may participate in iron transport in the tumor microenvironment. We describe how macrophages handle iron in the tumor microenvironment, discuss the relevance of an iron-release macrophage phenotype for tumor progression, and propose a new role for Lcn-2 in tumor-associated macrophages.
Background: The ligand-activated transcription factor, peroxisome-proliferator-activated receptor gamma (PPARγ), has been shown to play an essential role in immunosuppression during sepsis. PPARγ is upregulated in T cells of septic patients, sensitizing these cells to PPARγ-dependent apoptosis and thus contributing to T-cell depletion. In the polymicrobial cecum ligation and puncture (CLP) sepsis model in mice, both T-cell-specific gene knockout (Lck-Cre PPARγfl/fl) and systemic pharmacological PPARγ antagonism by GW9662 improved survival. Because GW9662 was only effective when applied 3 hours after CLP, we were interested to extend this time frame. For this reason we characterized the kinetics of SPPARγMs when administered before or in combination with the agonist thiazolidinedione, rosiglitazone.
Methods: A PPARγ-dependent transactivation assay was used in HEK293T cells. It is based on the vector pFA-PPARγ-LBD-GAL4-DBD encoding the hybrid protein PPARγ-LBD-GAL4-DBD and the reporter vector pFR-Luc, carrying a GAL4-responsive element in front of the Firefly luciferase gene. These two vectors were co-transfected, in combination with a control vector encoding Renilla luciferase (pRL-CMV) to normalize Firefly luciferase activity for transfection efficiency. Following transfection, cells were incubated with the SPPARγMs F-MOC and MCC-555 and the PPARγ antagonist GW9662 for different times (2 to 48 hours) and at increasing doses (0.01 to 10 μM), with or without rosiglitazone (0.01 to 10 μM). Transactivation was analyzed using a 96-well plate format.
Results: Rosiglitazone transactivated PPARγ in a time-dependent and dose-dependent manner, the response gradually increasing to a maximum at 48 hours with 10 μM. Low concentrations (0.01 to 0.1 μM) of SPPARγMs F-MOC and MCC-555 and the PPARγ antagonist GW9662 all exerted dose-independent antagonistic effects at an early incubation time point (2 hours). From 10 hours onwards, MCC-555 and GW9662, given alone, both exerted PPARγ agonistic effects, MCC-555 in parallel to responses to rosiglitazone, but GW9662 with characteristics of partial antagonism. F-MOC showed no dose-dependent effect at any concentration at later time points. Only GW9662 (1 to 10 μM) was able to inhibit rosiglitazone (0.1 to 1 μM)-induced PPARγ transactivation after 10 hours.
Conclusion: Our kinetic analysis reveals clear differences in the modulatory characteristics of PPARγ inhibitors, with previously unreported early inhibitory effects and late agonistic or partial agonistic activity. New SPPARγMs with extended inhibitory activity may prove useful in the therapy of sepsis.
Tight regulation of inflammation is very important to guarantee a balanced immune response without developing chronic inflammation. One of the major mediators of the resolution of inflammation is the transcription factor: the nuclear factor erythroid 2-like 2 (Nrf2). Stabilized following oxidative stress, Nrf2 induces the expression of antioxidants as well as cytoprotective genes, which provoke an anti-inflammatory expression profile, and is crucial for the initiation of healing. In view of this fundamental modulatory role, it is clear that both hyper- or hypoactivation of Nrf2 contribute to the onset of chronic diseases. Understanding the tight regulation of Nrf2 expression/activation and its interaction with signaling pathways, known to affect inflammatory processes, will facilitate development of therapeutic approaches to prevent Nrf2 dysregulation and ameliorate chronic inflammatory diseases. We discuss in this review the principle mechanisms of Nrf2 regulation with a focus on inflammation and autophagy, extending the role of dysregulated Nrf2 to chronic diseases and tumor development.
Einführung: Seit 20 Jahren ist die Vagusnervstimulation (VNS) eine europaweit zugelassene invasive Therapieoption für therapieresistente Depressionen (TRD). Im Gegensatz zu geläufigeren Behandlungen wie EKT sind Kenntnisse über VNS sowohl in der Allgemeinbevölkerung als auch in Fachkreisen gering.
Methoden: In diesem narrativen Review geben wir eine klinisch und wissenschaftlich fundierte Übersicht über die VNS. Hypothesen zum Wirkmechanismus sowie die aktuelle Evidenzlage zur Wirksamkeit werden dargestellt. Das perioperative Management, das Nebenwirkungsprofil und die Nachbetreuung einschließlich Dosistitration werden beschrieben. Ein Vergleich über internationale Leitlinienempfehlungen zur VNS findet sich ebenfalls. Ferner formulieren wir Kriterien, die bei der Auswahl geeigneter Patienten hilfreich sind.
Ergebnisse: Die elektrischen Impulse werden über den N. vagus afferent weitergeleitet und stimulieren über verschiedene Wege ein neuromodulatorisches zerebrales Netzwerk. Viele Studien und Fallserien zeigten die Wirksamkeit von VNS als adjuvantes Verfahren bei TRD. Der Effekt tritt mit einer Latenz von 3 bis 12 Monaten ein und steigt möglicherweise mit der Dauer der VNS. Unter der Beachtung der Stimulationsempfehlungen sind die Nebenwirkungen für die meisten Patienten tolerabel.
Fazit: Die VNS ist eine zugelassene, wirksame und gut verträgliche Langzeittherapie für chronische und therapieresistente Depressionen. Weitere Sham-kontrollierte Studien über einen längeren Beobachtungszeitraum sind zur Verbesserung der Evidenz wünschenswert.
While aberrant cells are routinely recognized and removed by immune cells, tumors eventually escape innate immune responses. Infiltrating immune cells are even corrupted by the tumor to acquire a tumor-supporting phenotype. In line, tumor-associated macrophages are well-characterized to promote tumor progression and high levels of tumor-infiltrating macrophages are a poor prognostic marker in breast cancer. Here, we aimed to further decipher the influence of macrophages on breast tumor cells and determined global gene expression changes in three-dimensional tumor spheroids upon infiltration of macrophages. While various tumor-associated mRNAs were upregulated, expression of the cytochrome P450 family member CYP1A1 was markedly attenuated. Repression of CYP1A1 in tumor cells was elicited by a macrophage-shaped tumor microenvironment rather than by direct tumor cell-macrophage contacts. In line with changes in RNA expression profiles, macrophages enhanced proliferation of the tumor cells. Enhanced proliferation and macrophage presence further correlated with reduced CYP1A1 expression in patient tumors when compared with normal tissue. These findings are of interest in the context of combinatory therapeutic approaches involving cytotoxic and immune-modulatory compounds.